Advertisement

Reactions Weekly

, Volume 1730, Issue 1, pp 113–113 | Cite as

Dasabuvir/ombitasvir/paritaprevir/ritonavir/sorafenib

Various toxicities: 3 case reports
Case report
  • 12 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series, a 71-year-old man developed cutaneous, digestive and hepatic toxicities as well as proteinuria during treatment with sorafenib for hepatocellular carcinoma (HCC) and headache, cutaneous and hepatic toxicities, loss of appetite and diarrhoea during treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir for hepatitis C virus (HCV) genotype 1b infection, a 62-year-old woman developed cutaneous toxicity and diarrhoea during treatment with sorafenib for HCC and fatigue during treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir for HCV genotype 1b infection, and a 62-year-old woman developed mild cutaneous toxicity, alopecia, elevated blood pressure, asthenia, anorexia, weight loss, dry skin, fatigue and muscular pain during treatment with...

Reference

  1. Revuelta-Herrero JL, et al. Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. Journal of Clinical Pharmacy and Therapeutics 43: 906-909, No. 6, Dec 2018. Available from: URL: http://doi.org/10.1111/jcpt.12727 - Spain

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations